<DOC>
	<DOCNO>NCT01401530</DOCNO>
	<brief_summary>The purpose Phase 1 study determine maximum tolerate dose ( MTD ) observation dose limit toxicity ( DLT ) , advance define , patient peripheral cutaneous T-cell lymphoma .</brief_summary>
	<brief_title>E7777 Treatment Patients With Peripheral T-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<criteria>lnclusion Criteria : Male female patient 20 less 80 year age time informed consent Patients histologically cytologically diagnosed peripheral T cell lymphoma Patients history chemotherapy ( include PUVA retinoid ) result relapse , recurrence treatment resistance ( administration E7777 alone ) Patients subject CHOP therapy without history prior treatment anthracycline anthraquinone anticancer drug ( administration E7777 combination CHOP therapy ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 No carryover beneficial adverse effect prior treatment may affect safety evaluation investigational drug ( exclude Grade 1 neuropathy alopecia ) Brain metastasis clinical symptom require treatment Serious systemic infection require intensive treatment Serious complication history History hypersensitivity protein therapeutic Known positive HIV antibody , HCV antibody , HBs antigen History malignancy peripheral Tcell lymphoma less five year elapse since last remission Patients undergone allogeneic hematopoietic stem cell transplantation Patients relapse within 6 month autologous hematopoietic stemcell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin</keyword>
	<keyword>T- Cell</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>lmmune System Diseases</keyword>
	<keyword>lmmunoproliferative Disorders</keyword>
</DOC>